3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Clear Cell
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Multiple Myeloma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
11
Cisplatin
8
pembrolizumab
2
Oxaliplatin
2
Nivolumab
2
Docetaxel
2
Capecitabine
2
trametinib
1
titanium silicide
1
telotristat ethyl
1
sovateltide
1
niraparib
1
milademetan
1
folfirinox
1
dostarlimab
1
devimistat
1
cytokine inducible SH2-containing protein
1
brigimadlin
1
bintrafusp alfa protein, human
1
becatecarin
1
adagrasib
1
Sorafenib
1
S 1 (combination)
1
Pancreaticojejunostomy
1
NUC-1031
1
Leucovorin
1
Hydroxychloroquine
1
Fluorouracil
1
Cetuximab
1
Catheter Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Biliary Tract Neoplasms
×
dostarlimab
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled